CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 210 enrolled
Drug / intervention
Pandemic influenza vaccine GSK2340272Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00964158
NCT00964158Phase 3Completed
CompareCT.gov

Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years

GlaxoSmithKline·interventional·Posted Aug 24, 2009·Updated Feb 19, 2018

In Brief

A Phase 3 clinical trial evaluating Pandemic influenza vaccine GSK2340272A for Influenza. Completed, enrolled 210 participants across 5 sites.

Detailed Summary

This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSpain
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2009
Enrollment StartSep 10, 2009
Primary CompletionNov 27, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.9 years ago

Interventions

Pandemic influenza vaccine GSK2340272Abiological

Two primary intramuscular (IM) injections and a booster IM injection